Tianjin Tianyao Pharmaceuticals Stock Beta
| 600488 Stock | 4.37 0.08 1.80% |
Tianjin Tianyao Pharmaceuticals fundamentals help investors to digest information that contributes to Tianjin Tianyao's financial success or failures. It also enables traders to predict the movement of Tianjin Stock. The fundamental analysis module provides a way to measure Tianjin Tianyao's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tianjin Tianyao stock.
Tianjin | Beta |
Tianjin Tianyao Pharmaceuticals Company Beta Analysis
Tianjin Tianyao's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Tianjin Tianyao Beta | 0.35 |
Most of Tianjin Tianyao's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tianjin Tianyao Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Tianjin Tianyao Pharmaceuticals has a Beta of 0.346. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The beta for all China stocks is notably lower than that of the firm.
Tianjin Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tianjin Tianyao's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tianjin Tianyao could also be used in its relative valuation, which is a method of valuing Tianjin Tianyao by comparing valuation metrics of similar companies.Tianjin Tianyao is currently under evaluation in beta category among its peers.
As returns on the market increase, Tianjin Tianyao's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tianjin Tianyao is expected to be smaller as well.
Tianjin Fundamentals
| Return On Equity | 0.0534 | ||||
| Return On Asset | 0.0237 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 4.73 B | ||||
| Shares Outstanding | 1.09 B | ||||
| Shares Owned By Insiders | 58.29 % | ||||
| Shares Owned By Institutions | 0.65 % | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 1.36 X | ||||
| Revenue | 3.78 B | ||||
| Gross Profit | 1.76 B | ||||
| EBITDA | 491.28 M | ||||
| Net Income | 117.05 M | ||||
| Total Debt | 270.25 M | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | 783.01 M | ||||
| Earnings Per Share | 0.14 X | ||||
| Target Price | 5.6 | ||||
| Number Of Employees | 2.68 K | ||||
| Beta | 0.35 | ||||
| Market Capitalization | 4.78 B | ||||
| Total Asset | 6.14 B | ||||
| Retained Earnings | 1.26 B | ||||
| Working Capital | 167.77 M | ||||
| Net Asset | 6.14 B | ||||
| Last Dividend Paid | 0.087 |
About Tianjin Tianyao Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tianjin Tianyao Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tianjin Tianyao using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tianjin Tianyao Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Tianjin Stock
Tianjin Tianyao financial ratios help investors to determine whether Tianjin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tianjin with respect to the benefits of owning Tianjin Tianyao security.